

OCT 16 1998

K982621

**510 (k) SUMMARY  
AS REQUIRED BY SECTION 807.92(C)**

**Identification:** QuickScreen™ At Home Drug Test (Model 9149 and 9150)

**Description:** Immunoassay for the qualitative detection of amphetamine, cocaine, methamphetamine, opiates, PCP and THC in urine.

**Name Of Manufacturer:** Phamatech  
9265 Activity Road #112  
San Diego, California 92126, USA

**Intended Use:** The QuickScreen™ At Home Drug Screening Test is a rapid, qualitative immunoassay for the detection of target drugs/metabolites in urine. The cut-off concentration for these tests is as follows: amphetamine; 1000 ng/ml, cocaine; 300 ng/ml, methamphetamine; 500 ng/ml, opiates; 300 ng/ml, PCP; 25 ng/ml and THC; 50 ng/ml. This assay is intended for use in the home to assist in preventing drug abuse. This kit is designed to incorporate a mechanism for anonymous confirmation testing to be performed at a certified laboratory.

**Technology:** The QuickScreen™ Test, like many commercially available drug screening test kits, qualitatively measures the presence of target drugs or their metabolites by visual color sandwich one step immunoassay technology. Examples of such predicate devices include the ABMC (Ancramdale, NY) and the Applied Biotech SureStep Test (San Diego, CA 92121). All of the above devices rely on the basic immunochemical sandwich assay principle of recognition and formation of specific antibody / target drug / antibody / complexes.

**Performance:** The product performance characteristics of the QuickScreen™ At Home Drug Test were evaluated in a clinical sample correlation study and a blind labeled spiked study. The results of these studies demonstrate the Phamatech QuickScreen™ Test to be substantially equivalent to the reported performance characteristics of other commercially available tests for the qualitative detection of the stated target drugs in urine. Correlations studies, using clinical specimens, produced a >99% correlation when compared to the Behring EMIT II (Cupertino, CA 95014) and GC/MS methodology. Clinical studies, performed at two independent laboratories, were also performed. In them the Phamatech QuickScreen™ exhibited excellent overall accuracy (>98%) in the hands of professional users. A consumer study was also performed, in it the QuickScreen™ At Home Drug Test exhibited excellent overall accuracy (>96%) in the hands of lay users.

**Conclusion:** For the reasons mentioned above, it may be concluded that the Phamatech QuickScreen™ At Home Drug Test is substantially equivalent to a variety of detection tests currently in commercial distribution and is safe in the hands of the lay user.



OCT 16 1998

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

Carl Mongiovi  
Director of Operations  
Phamatech  
9265 Activity Road #112/113  
San Diego, California 92126

Re: K982621  
QuickScreen™ At Home Drug Test  
Regulatory Class: II  
Product Code: MVO  
Dated: July 24, 1998  
Received: July 28, 1998

Dear Mr. Mongiovi:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Pre-market Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your pre-market notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.


Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,



Steven I. Gutman, M.D., M.B.A.  
Director  
Division of Clinical  
Laboratory Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

### INDICATIONS FOR USE

**Applicant:** Phamatech

**510 (k) Number (if known):** K982621

**Device Name:** QuickScreen™ At Home Drug Test


**Indications for Use:**

A home drug screening, and if needed, confirmation service. This kit provides a preliminary result for the detection/presence of the following drugs of abuse in urine: amphetamine, cocaine, methamphetamine, opiates, PCP and THC

**PLEASE DO NOT WRITE BELOW THIS LINE**

---

**Concurrence of the CDRH Office of Device Evaluation (ODE)**

  
Division Sign-Off)  
Division of Clinical Laboratory Devices  
510(k) Number K 98 2621

**Division Sign-off**  
**Division of Clinical Laboratory Devices**  
**510 (k) Number:**

**Prescription Use:** \_\_\_\_\_  
Per 21 CFR 801.109

OR

**Over the Counter:** ✓